A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Trial Profile

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Acute coronary syndromes; Myocardial infarction; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPROVE-IT
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 28 Feb 2017 Results (n=17717) assessing predictive role of TIMI Risk Score for Secondary Prevention to identify high-risk patients who benefit from the addition of ezetimibe to statin therapy, published in the Journal of the American College of Cardiology
    • 01 Dec 2016 Results assessing safety and efficacy of adding ezetimibe to simvastatin in a post acute coronary syndrome (ACS) population published in the American Heart Journal.
    • 16 Nov 2016 Results comparing cumulative incidence of CV and non-CV death for patients with STEMI and UA/NSTEMI over 7-year follow-up (n=6024) presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top